Eastern Cooperative Oncology Group
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private, Subsidiary
- Established
- 2012-01-01
- Employees
- 51
- Market Cap
- -
- Website
- https://ecog-acrin.org
Real-World Data Supports Efficacy of Opdivo Plus Yervoy in mRCC Treatment
A recent study highlights the real-world effectiveness of Opdivo (nivolumab) plus Yervoy (ipilimumab) as a first-line treatment for patients with intermediate- or poor-risk advanced metastatic renal cell carcinoma (mRCC), showing promising overall survival and progression-free survival rates.
IROX as Second-Line Therapy for Metastatic Colorectal Cancer
Recent studies highlight the effectiveness of IROX (Irinotecan plus Oxaliplatin) as a second-line therapy for metastatic colorectal cancer, showing superiority over single-agent treatments and offering new hope for patients with progressive disease.
Joseph Sparano Honored as Giant of Cancer Care for Contributions to Breast Cancer and HIV-Associated Cancer Research
• Dr. Joseph Sparano was recognized as a 2024 Giant of Cancer Care for his work in breast cancer and HIV-associated cancer, focusing on underserved communities.
• Sparano led pivotal trials like TAILORx, which refined treatment for ER-positive, HER2-negative breast cancer by using genomic testing to avoid unnecessary chemotherapy.
• His research addresses racial disparities in breast cancer outcomes, including the EAZ171 trial for Black women, and has improved treatments for HIV-associated lymphomas.
• Sparano's work extends to mentorship and compassionate care, shaping future oncologists and improving outcomes for diverse patient populations.
SBRT Followed by Chemoradiotherapy Shows Promise in Locally Advanced NSCLC
• A phase II trial evaluated stereotactic body radiotherapy (SBRT) to the primary lung tumor followed by chemoradiotherapy and consolidation immunotherapy in locally advanced NSCLC.
• The study did not meet its primary endpoint of 1-year progression-free survival, but showed favorable activity and safety profiles compared to other trials.
• Patients receiving consolidation durvalumab showed improved 1-year progression-free survival compared to the historical control rate.
• The findings support further investigation in the ongoing randomized phase 3 study NRG Oncology LU008.
Camrelizumab and Apatinib Show Promise in Neoadjuvant Treatment of TNBC
• Camrelizumab plus chemotherapy significantly improved pathologic complete response (pCR) rates in early or locally advanced triple-negative breast cancer (TNBC).
• Apatinib combined with sintilimab and chemotherapy demonstrated a high pCR rate of 70.6% in early TNBC, suggesting synergistic effects.
• Both camrelizumab and apatinib regimens exhibited manageable safety profiles, supporting their potential as new neoadjuvant therapeutic options.
• Biomarker analysis in the apatinib study identified correlations between immune response and pCR, offering insights for predicting treatment efficacy.
EUROPA Trial: Radiotherapy Preserves Quality of Life Better Than Endocrine Therapy in Older Breast Cancer Patients
• Interim analysis of the EUROPA trial reveals that radiotherapy is associated with better health-related quality of life (HRQOL) compared to endocrine therapy in older women with low-risk early breast cancer.
• The study, involving 731 women aged 70 and older, assessed HRQOL using the EORTC QOL Questionnaire-30, showing a smaller decline in global health status in the radiotherapy group at 24 months.
• Treatment-related adverse events were more frequent in the endocrine therapy group, with higher rates of arthralgia, fatigue, and hot flashes, leading to more treatment discontinuations.
• Researchers suggest radiotherapy may be a less burdensome alternative, but emphasize the need for further data on disease control outcomes to draw definitive conclusions.
Anlotinib Plus Chemotherapy Shows Promise in Advanced Gastrointestinal Cancers
• A phase II trial (ALTER-G-001) evaluates anlotinib combined with chemotherapy as first-line treatment for advanced gastrointestinal (GI) cancers with unresectable liver metastasis.
• In patients with stage IV colorectal cancer (CRC), anlotinib plus CAPEOX regimen demonstrated encouraging objective response rate (ORR) and disease control rate (DCR).
• For GI cancers other than CRC and ESCC, anlotinib combined with standard-of-care chemotherapy also showed promising ORR and DCR, warranting further investigation.
• The combination therapy exhibited manageable safety profiles, with adverse events being monitored and managed according to established guidelines.
Loncastuximab Tesirine Shows Promise in Relapsed/Refractory Follicular and Marginal Zone Lymphomas
• Loncastuximab tesirine with rituximab demonstrates a 97% overall response rate and a 67% complete response rate in relapsed/refractory follicular lymphoma patients.
• A phase II trial of loncastuximab tesirine alone shows a 91% overall response rate and a 70% complete response rate in relapsed/refractory marginal zone lymphoma.
• The combination therapy overcomes adverse prognostic factors, including POD24, in follicular lymphoma, offering a potential new treatment option.
• Both regimens exhibit manageable safety profiles, suggesting they could provide effective treatment with reduced toxicity for these lymphoma subtypes.
Bevacizumab Shows Superior Overall Survival Compared to Aflibercept in RAS Wild-Type Metastatic Colorectal Cancer
• A study comparing bevacizumab and aflibercept with FOLFIRI in patients with RAS wild-type metastatic colorectal cancer showed a statistically significant difference in overall survival.
• Patients receiving bevacizumab had a median overall survival of 14.2 months, compared to 11.2 months for those receiving aflibercept.
• Progression-free survival was also longer in the bevacizumab arm, with a median of 7.7 months versus 5.7 months in the aflibercept arm.
• Multivariable analysis identified tumor localization, albumin value, and treatment type as independent risk factors affecting overall survival.
Apatinib Plus DEB-TACE Improves Outcomes in Unresectable Hepatocellular Carcinoma
• A phase III trial demonstrated that combining apatinib with drug-eluting bead transarterial chemoembolization (DEB-TACE) significantly improved progression-free survival (PFS) in patients with unresectable hepatocellular carcinoma (uHCC).
• The study included patients with recurrence/metastasis confirmed by histopathology or cytology, who were ineligible for palliative surgery or radiotherapy.
• Apatinib, an oral tyrosine kinase inhibitor, was administered after DEB-TACE and continued until disease progression, intolerance, or death.
• The combination therapy showed manageable adverse events, suggesting a potential new treatment strategy for uHCC.
Neoadjuvant FOLFOX and Local Excision Show Promise in Organ Preservation for Low Rectal Cancer
• A new study demonstrates that neoadjuvant chemotherapy followed by local excision can effectively preserve organs in patients with node-negative low rectal cancer.
• The research found a 79% success rate in organ preservation with no local recurrences reported after a median follow-up of over 24 months.
• The treatment approach involves FOLFOX chemotherapy before tumor removal, followed by chemoradiation to target undetectable lymph nodes.
• This organ-preserving strategy offers a potential alternative to total mesorectal excision, which is associated with significant morbidity and mortality.
Novocure's Optune Lua Receives FDA Approval for Metastatic Non-Small Cell Lung Cancer
• The FDA has approved Novocure's Optune Lua for metastatic non-small cell lung cancer (mNSCLC) in adults who have progressed on or after platinum-based therapy.
• The approval was based on the Phase 3 LUNAR trial, which showed a statistically significant 3.3-month extension in median overall survival with Optune Lua.
• Patients receiving Optune Lua with PD-1/PD-L1 inhibitors experienced an 8-month extension in median overall survival compared to PD-1/PD-L1 inhibitors alone.
• Optune Lua is a wearable device delivering Tumor Treating Fields (TTFields) that disrupt cancer cell division, offering a novel approach with manageable skin-related side effects.
Secure Multiparty Computation Enables Privacy-Friendly Evaluation of Patient Data in Adrenal Gland Metastasis Study
• A bicenter, prospective, longitudinal observational study utilized MR-guided radiotherapy (MRgRT) to treat adrenal gland metastasis, emphasizing precision and minimizing radiation exposure.
• Secure multiparty computation (MPC) was employed to analyze patient data jointly between two sites while maintaining data privacy and adhering to strict data protection laws.
• The MPC framework, including Sharemind MPC and Federated Secure Computing, ensured that data remained within each clinical site, with only aggregate results accessible to researchers.
• This approach facilitated detailed studies on rare cancers like adrenal gland metastases, overcoming privacy obstacles and advancing personalized oncology through collaborative data analysis.
Surufatinib and Toripalimab Combination Shows Promise in Extensive-Stage Small Cell Lung Cancer
• A phase Ib/II study reveals that surufatinib combined with toripalimab, etoposide, and cisplatin demonstrates a high objective response rate (ORR) of 97.1% in ES-SCLC patients.
• The median progression-free survival (mPFS) reached 6.9 months, and the median overall survival (mOS) was 21.1 months, indicating a potential survival benefit.
• Common treatment-related adverse events included anemia, proteinuria, and decreased white blood cell count, but no unexpected safety signals were observed.
• Biomarker analysis suggests that low levels of serum neuron specific enolase (NSE) and pro-gastrin-releasing peptide (ProGRP) are associated with longer overall survival.
Lutetium-177 PSMA-617 Demonstrates Efficacy in Metastatic Castration-Resistant Prostate Cancer
• Lutetium-177 PSMA-617 (LuPSMA) significantly improved radiographic progression-free survival compared to changing androgen receptor pathway inhibitors (ARPI) in taxane-naive mCRPC patients.
• A confirmed prostate-specific antigen (PSA) response was observed in 51% of patients treated with LuPSMA, versus only 17% in the ARPI change group.
• Expanded access program data shows LuPSMA provides similar overall survival and PSA response rates to VISION trial, even in later-stage mCRPC patients.
• LuPSMA exhibits a favorable safety profile with a lower incidence of grade 3 or higher adverse events compared to ARPI, despite longer treatment exposure.
Nivolumab and Nab-Paclitaxel Show Promise in Muscle-Invasive Bladder Cancer
• A phase II trial (NURE-Combo) evaluated neoadjuvant nivolumab plus nab-paclitaxel followed by adjuvant nivolumab in muscle-invasive bladder cancer patients ineligible for cisplatin.
• The study met its primary endpoint, with 32.3% of patients achieving a pathologic complete response (ypT0N0) after neoadjuvant treatment and radical cystectomy.
• The combination demonstrated a manageable safety profile, with grade 3/4 treatment-related adverse events occurring in 25.8% of patients.
• These findings suggest a potential non-cisplatin-based chemoimmunotherapy approach for muscle-invasive bladder cancer, warranting further investigation.
Study of Adjuvant Cemiplimab Versus Placebo After Surgery for High-Risk Cutaneous Squamous Cell Carcinoma
A clinical trial is investigating the efficacy of adjuvant Cemiplimab compared to placebo in patients who have undergone surgery for high-risk cutaneous squamous cell carcinoma (CSCC). The study focuses on patients meeting specific inclusion criteria, such as age, disease status, and functional status, while excluding those with certain other malignancies or autoimmune diseases.
Axicabtagene Ciloleucel Shows Promise as Second-Line Therapy for Aggressive B-Cell Lymphoma
• Axicabtagene ciloleucel (axi-cel) demonstrated a 71% complete metabolic response rate at 3 months in patients with relapsed or refractory aggressive B-cell lymphoma ineligible for stem cell transplant.
• The study reported a manageable safety profile, with cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome being the most common adverse events.
• At a median follow-up of 12 months, the estimated overall survival rate was 78.3%, suggesting a potential survival benefit with axi-cel in this patient population.
• These findings support axi-cel as an effective second-line treatment option, particularly for older patients and those with comorbidities.
Socazolimab Plus Chemotherapy Shows Promise in Neoadjuvant Treatment for ESCC
• A Phase II trial evaluated socazolimab with nab-paclitaxel and cisplatin (TP) as neoadjuvant therapy for ESCC.
• The combination showed a higher pathological complete response (pCR) rate of 41.4% compared to 27.6% with TP alone.
• The proportion of patients achieving complete regression of the primary tumor (ypT0) was significantly higher in the socazolimab group.
• The study suggests socazolimab + TP is a promising neoadjuvant strategy, warranting further investigation in larger trials.
Phase 1b Clinical Trial Results for Socazolimab in ES-SCLC Treatment
A phase 1b clinical trial investigated the safety and efficacy of socazolimab, a PD-L1 monoclonal antibody, combined with etoposide and carboplatin (EC) for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC). The study, involving 20 patients, showed promising results with a median progression-free survival (PFS) of 5.65 months and median overall survival (OS) of 14.88 months. The treatment was well-tolerated, with manageable adverse events, indicating potential survival benefits for ES-SCLC patients.
© Copyright 2025. All Rights Reserved by MedPath